Patricia A. Cronin, M.D.

Closed for Enrollment

• AFT-25, Comparing an Operation to Monitoring, with and without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (COMET) Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

  This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.